MK-8189 Safety and Tolerability in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis (MK-8189-017)

Alzheimer's Disease Clinical Trial

Official title:

A Randomized Clinical Study to Evaluate the Safety and Tolerability of MK-8189 in Participants With Alzheimer's Disease With or Without Symptoms of Agitation-Aggression and/or Psychosis

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05227118
• Other study ID #: 8189-017
• Secondary ID: MK-8189-017
• Status: Completed
• Phase: Phase 1
• Start date: July 1, 2022
• Est. completion date: January 10, 2023

Study information

• Verified date: January 2023
• Source: Merck Sharp & Dohme LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of MK-8189 in participants with Alzheimer's Disease (AD) with or without symptoms of agitation-aggression and/or psychosis.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 29
• Est. completion date: January 10, 2023
• Est. primary completion date: January 10, 2023
• Accepts healthy volunteers: No
• Gender: All
• Age group: 65 Years to 85 Years

Eligibility

The main inclusion and exclusion criteria include but are not limited to the following:

Inclusion Criteria:

• Has a documented diagnosis of probable Alzheimer Disease based on National Institute on Aging-Alzheimer Association criteria for AD, with a history of cognitive and functional decline with gradual onset and slow progression for at least 1 year before screening, that is either corroborated by an informant who knows the participant well or is documented in medical records

• Lives in the community setting with a reliable trial partner/caregiver or lives alone in an assisted living facility, with supervision and has a reliable trial partner/caregiver

• Has a reliable and competent trial partner/caregiver who must have a close relationship with the participant and is knowledgeable of the participant's condition and progress and able to read, understand and speak the designated language at the study site

• Can read at the 6th grade level/equivalent as determined by the investigator

• Has an academic and/or employment history sufficient to exclude intellectual disability and is able, in the opinion of the investigator, to fully participate in the study

• Participants receiving treatment with a cholinesterase inhibitor or other treatment for AD, must have been on a stable regimen for 3 months prior to screening and there are no expected changes in co-medication during the study

• Is able to discontinue any antipsychotic medication they are taking at the time of Screening

• Has a body mass index (BMI) > 18 and = 35kg/m2, inclusive

Exclusion Criteria:

• Has agitation/aggression or psychosis that is attributable to concomitant medications, environmental conditions, substance abuse, or an active medical or psychiatric condition

• Has a known history of stroke or evidence from prior magnetic resonance imaging (MRI) scan (if available) that is clinically important in the investigator's opinion

• Has evidence of a clinically relevant neurological disorder other than the disease being studied (i.e., probable AD) at Screening

• Has a history of seizures or epilepsy within the last 5 years before Screening

• Has evidence of a clinically relevant or unstable psychiatric disorder

• Is at imminent risk of self-harm

• Has a history of alcoholism or drug dependency/abuse within the last 5 years before Screening

• Has a history of cancer (malignancy). Exceptions: (1) Adequately treated non-melanomatous skin carcinoma or carcinoma in situ of the cervix or; (2) Other malignancies that have been successfully treated with appropriate follow up and therefore unlikely to recur for the duration of the study

• Has a family history of long QT syndrome

• Previously developed severe extrapyramidal symptoms (EPS) following administration of any prescribed medication or study treatment

• Is positive for hepatitis B surface antigen (HBsAg), hepatitis C antibodies or human immunodeficiency virus (HIV)

• Had major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the pre-study (screening) visit

• Consumes greater than 3 glasses of alcoholic beverages per day

• Consumes excessive amounts, defined as greater than 6 servings (1 serving is approximately equivalent to 120 mg of caffeine) of coffee, tea, cola, energy drinks, or other caffeinated beverages per day

• Is a regular user of cannabis, any illicit drugs or has a history of drug (including alcohol) abuse within approximately 3 years

Related Conditions & MeSH terms

• Aggression
• Alzheimer Disease
• Alzheimer's Disease

Intervention

Drug:
• MK-8189
MK-8189 administered orally once a day (QD) at a titration via tablet in 4 mg and 12 mg dose strengths
• Placebo
MK-8189 matching placebo administered orally QD

Locations

Country	Name	City	State
United States	Atlanta Center for Medical Research ( Site 0004)	Atlanta	Georgia
United States	Top Medical Research ( Site 0005)	Cutler Bay	Florida
United States	iResearch Atlanta ( Site 0009)	Decatur	Georgia
United States	Velocity Clinical Research, Hallandale Beach ( Site 0001)	Hallandale Beach	Florida
United States	Well Pharma Medical Research, Corp. ( Site 0006)	Miami	Florida
United States	Global Medical Institutes LLC; Princeton Medical Institute ( Site 0008)	Princeton	New Jersey
United States	CITrials ( Site 0007)	Santa Ana	California
United States	Richmond Behavioral Associates ( Site 0003)	Staten Island	New York

Sponsors (1)

Lead Sponsor	Collaborator
Merck Sharp & Dohme LLC

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of participants who experienced an adverse event (AE)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE will be reported.	Up to approximately 42 days
Primary	Number of participants discontinuing study treatment due to an Adverse Event (AE)	An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who discontinued study treatment due to an AE will be reported.	Up to approximately 28 days